Emcure Launches Landmark Weight Loss Drug in India

Emcure Pharmaceuticals has launched Poviztra, a semaglutide injection for weight loss, marking a first for an Indian company. The drug is aimed at managing chronic weight issues and reducing cardiovascular risks, amidst India's burgeoning obesity crisis.

Emcure Pharmaceuticals has taken a significant step by launching Poviztra, a semaglutide injection designed for weight loss, throughout India as of Monday.

This venture makes Emcure the first Indian company to introduce and distribute Poviztra, a vital addition in the fight against obesity, with prices starting at Rs 8,790 a month.

The CEO, Satish Mehta, emphasized this launch as crucial in providing scientifically proven solutions to manage the widespread obesity crisis affecting millions in India.